Windtree Therapeutics rises on licensing deal for birth control vaginal gel

Windtree Therapeutics

20/03/2025 18:20

** Shares of biotechnology firm Windtree Therapeutics WINT.O rise 27.8% to $2.16 in afternoon trading

** WINT says it has entered into a licensing deal with Evofem Biosciences EVFM.PK for its birth control vaginal gel, Phexxi

    ** WINT will serve as the sourcing partner to Evofem and aims to produce Phexxi at a cheaper cost

** Co says Evofem will maintain ownership of the asset and continue to commercialize Phexxi in the U.S. and internationally

** Up to last close, WINT has fallen 99.4% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))